Cargando…

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

BACKGROUND: Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited as these subtypes are relatively rare compared to cutaneo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogata, Dai, Haydu, Lauren E., Glitza, Isabella C., Patel, Sapna P., Tawbi, Hussein A., McQuade, Jennifer L., Diab, Adi, Ekmekcioglu, Suhendan, Wong, Michael K., Davies, Michael A., Amaria, Rodabe N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982611/ https://www.ncbi.nlm.nih.gov/pubmed/33686688 http://dx.doi.org/10.1002/cam4.3781

Ejemplares similares

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
por: Fischer, Grant M., et al.
Publicado: (2020)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real‐world study
por: Tawbi, Hussein, et al.
Publicado: (2021)

Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma
por: Tawbi, Hussein, et al.
Publicado: (2022)

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
por: Glitza Oliva, Isabella C., et al.
Publicado: (2023)

The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival
por: Ogata, Dai, et al.
Publicado: (2020)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Sloane, Robert A. Szczepaniak, et al.
Publicado: (2021)

Complete spontaneous regression of a metastatic acral melanoma with associated leukoderma
por: Spring, Isobel R., et al.
Publicado: (2017)

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H, et al.
Publicado: (2018)

GNAQ mutation in a patient with metastatic mucosal melanoma
por: Kim, Chung-Young, et al.
Publicado: (2014)

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective
por: Jung, Seungyeon, et al.
Publicado: (2022)

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
por: Beck, Kristen M., et al.
Publicado: (2016)

Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H., et al.
Publicado: (2019)

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021)

Data mining of immune-related prognostic genes in metastatic melanoma microenvironment
por: Han, Wei, et al.
Publicado: (2020)

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
por: ERIKSSON, Hanna, et al.
Publicado: (2020)

Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments
por: He, Zan, et al.
Publicado: (2022)

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
por: Zou, Fangwen, et al.
Publicado: (2021)

Management of metastatic cutaneous melanoma: updates in clinical practice
por: Schvartsman, Gustavo, et al.
Publicado: (2019)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
por: Gambichler, Thilo, et al.
Publicado: (2017)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Characterization of the melanoma brain metastatic niche in mice and humans
por: Amit, Moran, et al.
Publicado: (2013)

Advanced Acral Melanoma Therapies: Current Status and Future Directions
por: Zhang, Yiqun, et al.
Publicado: (2022)

iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation
por: Ding, Zhen, et al.
Publicado: (2021)

Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
por: Wang, Meng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prul4oshn0k8h8r4vop9au04t4